Mission Wealth Management LP Grows Stock Position in Merck & Co., Inc. $MRK

Key Points

• Mission Wealth Management increased its Merck stake by 178.1% in the second quarter, ending with 72,281 shares worth approximately $9.29 million. Institutional investors collectively own 76.07% of MRK.
• Merck exceeded quarterly expectations with $16.61 billion in revenue and adjusted EPS above consensus, while revenue rose 5.1% year over year. The company also declared a quarterly dividend of $0.85 per share, or $3.40 annualized.
• Analyst sentiment remains favorable, with a consensus “Moderate Buy” rating and a $135.50 target price, but insider selling, high valuation and future Keytruda patent expirations remain risks.

Mission Wealth Management LP raised its stake in Merck & Co., Inc. (NYSE:MRK - Free Report) by 178.1% in the 2nd quarter, according to its most recent disclosure with the SEC. The fund owned 72,281 shares of the company's stock after purchasing an additional 46,291 shares during the quarter. Mission Wealth Management LP's holdings in Merck & Co., Inc. were worth $9,288,000 at the end of the most recent quarter.

Several other hedge funds also recently made changes to their positions in MRK. Walled Lake Planning & Wealth Management LLC raised its holdings in Merck & Co., Inc. by 1.4% during the 2nd quarter. Walled Lake Planning & Wealth Management LLC now owns 48,113 shares of the company's stock valued at $6,183,000 after buying an additional 669 shares during the last quarter. Hughes Financial Services LLC grew its holdings in Merck & Co., Inc. by 10.4% in the 2nd quarter. Hughes Financial Services LLC now owns 1,162 shares of the company's stock worth $149,000 after acquiring an additional 109 shares during the last quarter. Sowell Financial Services LLC grew its holdings in Merck & Co., Inc. by 0.6% in the 2nd quarter. Sowell Financial Services LLC now owns 75,015 shares of the company's stock worth $9,639,000 after acquiring an additional 466 shares during the last quarter. AA Financial Advisors LLC purchased a new position in shares of Merck & Co., Inc. in the second quarter valued at about $209,000. Finally, Marshall Financial Group LLC increased its position in shares of Merck & Co., Inc. by 10.4% in the second quarter. Marshall Financial Group LLC now owns 35,820 shares of the company's stock valued at $4,603,000 after acquiring an additional 3,378 shares during the period. 76.07% of the stock is owned by hedge funds and other institutional investors.

Merck & Co., Inc. Price Performance

Shares of NYSE MRK opened at $133.10 on Thursday. Merck & Co., Inc. has a fifty-two week low of $77.58 and a fifty-two week high of $135.05. The company has a 50 day simple moving average of $124.94 and a two-hundred day simple moving average of $119.64. The company has a market capitalization of $328.38 billion, a price-to-earnings ratio of 106.48, a P/E/G ratio of 5.62 and a beta of 0.19. The company has a debt-to-equity ratio of 1.02, a quick ratio of 1.06 and a current ratio of 1.30.

Merck & Co., Inc. (NYSE:MRK - Get Free Report) last issued its quarterly earnings results on Tuesday, August 4th. The company reported ($0.13) EPS for the quarter, topping analysts' consensus estimates of ($0.26) by $0.13. The firm had revenue of $16.61 billion for the quarter, compared to analysts' expectations of $16.37 billion. Merck & Co., Inc. had a return on equity of 16.05% and a net margin of 4.77%.The business's revenue for the quarter was up 5.1% compared to the same quarter last year. During the same period in the previous year, the firm posted $2.13 EPS. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS. Analysts expect that Merck & Co., Inc. will post 2.77 EPS for the current fiscal year.

Merck & Co., Inc. Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 7th. Shareholders of record on Tuesday, September 15th will be paid a dividend of $0.85 per share. The ex-dividend date is Tuesday, September 15th. This represents a $3.40 dividend on an annualized basis and a yield of 2.6%. Merck & Co., Inc.'s payout ratio is presently 272.00%.

Analyst Upgrades and Downgrades

MRK has been the subject of a number of analyst reports. Scotiabank increased their target price on shares of Merck & Co., Inc. from $136.00 to $155.00 and gave the stock a "sector outperform" rating in a report on Tuesday, June 30th. Argus boosted their price target on Merck & Co., Inc. from $130.00 to $145.00 and gave the company a "buy" rating in a report on Tuesday. Barclays upped their price target on Merck & Co., Inc. from $140.00 to $150.00 and gave the company an "overweight" rating in a research report on Wednesday, July 29th. Cantor Fitzgerald reiterated a "neutral" rating and issued a $120.00 price objective on shares of Merck & Co., Inc. in a report on Monday, July 6th. Finally, Bank of America boosted their target price on Merck & Co., Inc. from $130.00 to $141.00 and gave the company a "buy" rating in a research note on Tuesday, June 30th. Fifteen equities research analysts have rated the stock with a Buy rating and seven have assigned a Hold rating to the stock. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $135.50.

Insider Buying and Selling

In other news, EVP David Michael Williams sold 52,847 shares of Merck & Co., Inc. stock in a transaction dated Wednesday, August 5th. The stock was sold at an average price of $128.77, for a total value of $6,805,108.19. Following the completion of the transaction, the executive vice president owned 31,716 shares of the company's stock, valued at $4,084,069.32. The trade was a 62.49% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Chirfi Guindo sold 15,000 shares of the company's stock in a transaction dated Thursday, August 6th. The stock was sold at an average price of $131.00, for a total transaction of $1,965,000.00. Following the completion of the transaction, the executive vice president owned 46,613 shares in the company, valued at approximately $6,106,303. The trade was a 24.35% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders sold 137,923 shares of company stock valued at $17,908,943. 0.17% of the stock is owned by insiders.

Trending Headlines about Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Analyst sentiment improved: Daiwa Securities upgraded Merck to “outperform” and set a $143 price target, while Argus raised its target to $145 and maintained a “buy” rating. These targets imply additional upside from recent trading levels. Daiwa Securities upgrade
• Positive Sentiment: RSV expansion opportunity: The FDA and European Medicines Agency accepted supplemental applications for broader use of ENFLONSIA to prevent RSV in vulnerable young children. The regulatory reviews could expand Merck’s growth beyond oncology and help diversify the portfolio ahead of Keytruda’s future patent expirations. Merck RSV regulatory review article
• Positive Sentiment: Estimates edged higher: Erste Group raised its FY2026 earnings forecast for Merck to $2.75 per share from $2.70, broadly aligning with the $2.76 consensus estimate. The company also recently exceeded quarterly revenue and adjusted earnings expectations, reporting $16.61 billion in revenue.
• Positive Sentiment: Core business remains solid: Keytruda, oncology and animal health supported quarterly growth, while the company continues investing in its pipeline. Merck also declared its regular $0.85 quarterly dividend, equivalent to a $3.40 annualized payout.
• Neutral Sentiment: Vaccine-policy uncertainty: Reports that the administration may seek to split the MMR vaccine into separate shots could create headlines around the broader vaccine market, but experts say the proposal lacks scientific support and is unlikely to advance. MMR vaccine policy article
• Negative Sentiment: Repeated insider selling: EVP Richard R. Deluca sold roughly 45,000 shares across transactions from August 6 through August 12 for approximately $6.7 million. Although he retained a substantial position, the sales may weigh modestly on sentiment.
• Negative Sentiment: Longer-term risks persist: Analysts continue to flag falling estimates, a high valuation and upcoming patent expirations, particularly the eventual loss of Keytruda exclusivity. These issues could limit upside unless Merck’s pipeline and newer products offset the expected revenue pressure.

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source